DFTX logo

Definium Therapeutics Inc. (DFTX)

$29.38

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on DFTX

Market cap

$4.02B

EPS

-3.12

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

2.24184

Price on DFTX

Previous close

$30.16

Today's open

$30.05

Day's range

$28.44 - $30.52

52 week range

$10.46 - $49.70

Profile about DFTX

CEO

Robert Barrow

Employees

105

Headquarters

New York, NY

Exchange

Nasdaq Global Select

Shares outstanding

136899935

Issue type

Common Stock

DFTX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on DFTX

Definium Therapeutics: 3 Key Takeaways for Long-Term Investors

Definium Therapeutics held $1.05 billion in cash on Sept. 30, 2026. Management expects cash resources to fund planned operations into 2030.

news source

The Motley Fool • Nov 16, 2026

news preview

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

Definium Therapeutics NASDAQ: DFTX plans to submit a new drug application to the U.S. Food and Drug Administration for its LSD formulation DT120 in the first half of next year, following positive results from three Phase 3 studies, Chief Medical Officer Daniel Karlin said.

news source

MarketBeat • Nov 11, 2026

news preview

Definium Therapeutics, Inc. (DFTX) Q3 2026 Earnings Call Transcript

Definium Therapeutics, Inc. (DFTX) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 10, 2026

news preview

Definium Q3 Earnings: Psychedelics Approval Beckons But Valuation Seems Inflated

Definium Therapeutics, Inc. reported strong Phase 3 results for DT120 in both GAD and MDD, positioning for an NDA filing in H1 2026. DFTX holds over $1bn in cash, supporting operations into 2030, and is preparing for a potential commercial launch in 2027. Despite class-leading efficacy data and regulatory momentum, I maintain a Hold rating due to high valuation, patent challenges, and uncertain market dynamics.

news source

Seeking Alpha • Nov 10, 2026

news preview

What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call

Definium Therapeutics NASDAQ: DFTX plans to file a new drug application for its psychiatric treatment candidate DT120 ODT in the first half of 2027, following positive results from three Phase 3 studies in generalized anxiety disorder and major depressive disorder, executives said on the company's third-quarter earnings call.

news source

MarketBeat • Nov 10, 2026

news preview

Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

NEW YORK--(BUSINESS WIRE)-- #GAD--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported financial results for the quarter ended September 30, 2026, and recent highlights. The Company also reported positive initial results from its Phase 2a trial of DT402 in adults with ASD, with improvements obser.

news source

Business Wire • Nov 9, 2026

news preview

Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to ten newly hired non-executive employees consisting of options to purchase an aggregate of 269,800 common shares of the Company (the "Options") with effective grant dates of November 9, 20.

news source

Business Wire • Nov 9, 2026

news preview

Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress

NEW YORK--(BUSINESS WIRE)-- #ClinicalTrials--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced four poster presentations at the 2026 NEI Fall Congress taking place November 5 through 8 in Colorado Springs, CO. Positive topline results from Panorama, the Company's second Phase 3 study of DT120 (lysergide.

news source

Business Wire • Nov 4, 2026

news preview

Definium Therapeutics to Participate at Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company's management team will participate in the following investor conferences: Stifel 2026 Healthcare Conference Fireside Chat Date and Time: Tuesday, November 10, 2026 at 9:20 AM ET Loc.

news source

Business Wire • Nov 3, 2026

news preview

Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a webcast at 4:30 p.m. EST on Monday, November 9, 2026 to report financial results for the third quarter ended September 30, 2026, and discuss recent business highlights.Listeners can register for the webcast via this link.

news source

Business Wire • Oct 29, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Definium Therapeutics Inc.

Open an M1 investment account to buy and sell Definium Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in DFTX on M1